SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) ...
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the ...
A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact ...
Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...
This study provides valuable insights into the role of the NF-kB and IKK signaling pathways in γδ T cell development and survival, using robust genetic mouse models. While the research is ...
A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key ...
Chimeric antigen receptor (CAR) T-cell therapies have transformed cancer and autoimmune disease treatment. Modified CAR proteins equip T cells with the ability to identify and eliminate cancer cells ...
The U.S. Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy designation to MB-105, a CD5 ...
The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback